Jong Yoo, MD
Internal Medicine · Carrollton, TXNPI 1932111614
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novartis at 36.5% of the total. Reporting peaked in 2019 at $185 and has fallen 92.4% since, to $14 in 2021. That places this record below the midpoint for internal medicine clinicians in TX, where the typical reported total is $270.
Across 15 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$99
- Bayer$51
- AbbVie$22
- Tesaro, Inc.$22
- AMAG Pharmaceuticals, Inc.$20
- Coherus Oncology, Inc.$15
- plus $42 from 3 others
What the payments were for
- Food & beverage$271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $99 |
| Bayer | 3 | $51 |
| AbbVie | 1 | $22 |
| Tesaro, Inc. | 1 | $22 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| AstraZeneca | 1 | $13 |
How this compares
$271 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $16,011 |
| VascepaIcosapent Ethyl | 27 | $15,252 |
| XareltoRivaroxaban | 14 | $10,985 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $10,950 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 19 | $1,096 |
| Megestrol Acetate | 14 | $897 |
| Atorvastatin Calcium | 131 | $769 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 59 | $595 |
| Tamsulosin Hcl | 61 | $573 |
| Amlodipine Besylate | 111 | $553 |
| Rosuvastatin Calcium | 72 | $522 |
| Losartan Potassium | 85 | $453 |
| Diclofenac Sodium | 26 | $387 |
| Pantoprazole Sodium | 41 | $383 |
| Levothyroxine Sodium | 33 | $357 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Carrollton
- Henry PunziCarrollton$120K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.